Oxalis Labs – FDA 483, Apr 24, 2026

Oxalis Labs, a drug manufacturer in Solan, India, was cited by the FDA for significant deficiencies during an inspection. The firm failed to establish adequate written procedures for production and process controls, including a lack of independent validation for critical test parameters. Additionally, the inspection revealed unrepresentative in-process sampling methods and inadequately qualified manufacturing equipment.